Welcome to our dedicated page for Opus Genetics SEC filings (Ticker: IRD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating trial data, milestone payments or FDA correspondence in Opus Genetics’ filings can feel like searching for a strand of DNA in a haystack. Gene-therapy companies must disclose complex clinical details, and Opus Genetics is no exception—its 10-K often exceeds 200 pages and 8-K updates arrive whenever a study meets a safety endpoint. Stock Titan’s AI-powered analysis turns that complexity into clarity, so you won’t miss the disclosures that move a biotech valuation.
Whether you need the latest Opus Genetics quarterly earnings report 10-Q filing, a concise view of Opus Genetics insider trading Form 4 transactions, or a quick brief on an Opus Genetics 8-K material events explained, our platform delivers answers in seconds. AI summaries highlight R&D expense shifts, orphan-drug designations and partnership milestones, while real-time alerts flag Opus Genetics Form 4 insider transactions real-time—key signals for gauging executive confidence. You can also drill into the proxy to see Opus Genetics executive compensation without wading through legalese.
Here’s how professionals use these insights:
- Compare quarter-over-quarter burn rates straight from the 10-Q.
- Track manufacturing-scale updates via 8-K filings before market open.
- Monitor Opus Genetics executive stock transactions Form 4 for alignment with pivotal trial milestones.
From an Opus Genetics annual report 10-K simplified to an Opus Genetics earnings report filing analysis, every document is parsed, tagged and explained. Stop downloading PDFs and start understanding Opus Genetics SEC documents with AI—all in one place and updated the moment EDGAR posts.
Opus Genetics (IRD) reported an insider transaction on a Form 4. On 10/22/2025, a transaction in Common Stock with code F involved 23,795 shares at $1.95. After this activity, the reporting person beneficially owns 319,005 shares, held directly.
The reporting person is listed as a Director and Officer (President), and the filing was made by one reporting person.
Opus Genetics, Inc. filed a Form S-8 on September 26, 2025 to register securities under its 2020 Equity Incentive Plan. The filing incorporates by reference the company’s 2024 Annual Report (filed March 31, 2025), subsequent quarterly reports (filed May 15, 2025 and August 13, 2025) and multiple current reports filed between January 7, 2025 and September 2, 2025. The Registration Statement relies on prior effective S-8 registrations and includes customary exhibits and a power of attorney signed by management and directors.
FAQ
What is the current stock price of Opus Genetics (IRD)?
What is the market cap of Opus Genetics (IRD)?
